Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.

Autor:	Sen P; NIHR Moorfields Biomedical Research Centre, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom., Gurudas S; UCL Institute of Ophthalmology, London, United Kingdom., Ramu J; NIHR Moorfields Biomedical Research Centre, London, United Kingdom., Patrao N; NIHR Moorfields Biomedical Research Centre, London, United Kingdom., Chandra S; NIHR Moorfields Biomedical Research Centre, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom., Rasheed R; NIHR Moorfields Biomedical Research Centre, London, United Kingdom., Nicholson L; NIHR Moorfields Biomedical Research Centre, London, United Kingdom., Peto T; NetwORC UK Reading Centre, Queen's University of Belfast, Belfast, United Kingdom., Sivaprasad S; NIHR Moorfields Biomedical Research Centre, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom. Electronic address: Sobha.sivaprasad@nhs.net., Hykin P; NIHR Moorfields Biomedical Research Centre, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Ophthalmology. Retina [Ophthalmol Retina] 2021 Nov; Vol. 5 (11), pp. 1115-1124. Date of Electronic Publication: 2021 Feb 19.
DOI:	10.1016/j.oret.2021.02.008
Abstrakt:	Purpose: To evaluate whether baseline demographic, clinical, and OCT characteristics predict visual acuity (VA) outcomes in patients receiving anti-vascular endothelial growth factor (VEGF) therapy for macular edema (ME) due to central retinal vein occlusion (CRVO). Design: Post hoc analysis of the randomized noninferiority trial (Lucentis, Eylea, Avastin in CRVO) LEAVO Study from December 12, 2014, to December 16, 2016, carried out across 44 UK National Health Service ophthalmology departments. Participants: Data on 267 participants with a baseline best-corrected mean visual acuity (BCVA) range of 19 to 78 Early Treatment Diabetic Retinopathy Study letter score (approximate Snellen equivalent, 20/32 to 20/320) who had central subfield thickness (CST) ≥ 320 μm on Spectralis OCT (Heidelberg Engineering) were analyzed. Methods: Study participants were randomized to receive repeated intravitreal injections of ranibizumab (0.5 mg/50 μl), aflibercept (2.0 mg/50 μl), or bevacizumab (1.25 mg/50 μl), and a protocol-driven pro re nata re-treatment regimen at 4 to 8 weekly visits was followed up to week 100 after 4 mandated 4-weekly loading injections. Main Outcome Measures: Change in BCVA and percentage of patients gaining ≥ 10 letters and achieving BCVA letter score > 70 letters at 52 and 100 weeks. Results: The analysis was adjusted for treatment effects and confirmed by sensitivity analysis. Age ≥ 75 years is a poor predictor for all 3 visual outcomes. Lower baseline BCVA predicted 10-letter gainers and higher gains in BCVA, although it is a poor predictor of achieving > 70 Early Treatment Diabetic Retinopathy Study letters. None of the baseline OCT morphologic characteristics except ellipsoid zone (EZ) integrity influenced any visual outcomes. Both baseline CST and total macular volume showed a nonlinear relation to 10-letter gainers, with CST > 900 μm being a poor prognostic indicator. Baseline CST and macular volume did not predict mean change in BCVA or BCVA > 70 letters at 52 and 100 weeks. The sensitivity analysis conclusions after removing iCRVO were similar. Conclusions: At presentation, younger age, higher baseline BCVA, and a definitely intact subfoveal EZ are predictors of BCVA score > 70 letters at 100 weeks. (Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu